Granules India Share Price

The Sales for the quarter ended September 2022 of Rs. 9635.77 millions rose by 36.93% from Rs. 7036.94 millions.The company almost doubled its revenue to Rs. 1089.29 millions  from Rs. 460.96 millions in the quarter ended September 2022.The company reported a good operating profit of 1894.14 millions compared to 976.97 millions of corresponding previous quarter.

The revenue zoomed 16.03% to Rs. 10323.91 millions for the quarter ended December 2022 as compared to Rs. 8897.79 millions during the corresponding quarter last year.A slim rise of 15.22% was recorded in the Net profit for the quarter ended December 2022 to Rs. 1397.99  millions  From Rs. 1213.29 millions.Operating profit surged to 2376.91 millions from the corresponding previous quarter of 1968.24 millions.

The revenue zoomed 16.03% to Rs. 10323.91 millions for the quarter ended December 2022 as compared to Rs. 8897.79 millions during the corresponding quarter last year.Modest increase of 15.22% in the Net Profit was reported from. 1213.29 millions to Rs. 1397.99  millions.Operating Profit saw a handsome growth to 2376.91 millions from 1968.24 millions in the quarter ended December 2022.

With respect to its communication dated July 23, 2022, regarding the US FDA inspection of Granules Pharmaceuticals, Inc. (GPI), a wholly-owned foreign subsidiary of the Company located in Chantilly, Virginia, USA and issuance of Form 483 with 6 observations. Granules India has informed that the GPI has received a communication from the US FDA indicating the inspection classification as ‘Voluntary Action Indicated.’ (VAI). The VAI inspection classification indicates that the US FDA will not take or recommend regulatory or enforcement action because the observations do not meet the threshold for action at this time.

The above information is a part of company’s filings submitted to BSE.

The company now have a total of 51 ANDA approvals from US FDA

Granules India is currently trading at Rs. 310.65, up by 4.15 points or 1.35% from its previous closing of Rs. 306.50 on the BSE.

The scrip opened at Rs. 310.00 and has touched a high and low of Rs. 312.95 and Rs. 308.00 respectively. So far 31785 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 362.25 on 14-Jan-2022 and a 52 week low of Rs. 227.00 on 20-Jun-2022.

Last one week high and low of the scrip stood at Rs. 314.90 and Rs. 303.15 respectively. The current market cap of the company is Rs. 7697.08 crore.

The promoters holding in the company stood at 41.98%, while Institutions and Non-Institutions held 26.16% and 31.85% respectively.

Granules India has received approval from US Food & Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Guaifenesin and Pseudoephedrine Hydrochloride Extended-Release (ER) Tablets, 600 mg/60 mg and 1200 mg/120 mg (OTC). It is bioequivalent to the reference listed drug product, Mucinex D Extended-Release Tablets, 600 mg/60 mg and 1200 mg/120 mg, of RB Health (US) LLC.

Guaifenesin and Pseudoephedrine Hydrochloride ER Tablets are used to loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive; temporarily relieve nasal congestion due to common cold, hay fever, upper respiratory allergies; temporarily restores freer breathing through the nose; promotes nasal and/or sinus drainage; and temporarily relieves sinus congestion and pressure. Granules now have a total of 51 ANDA approvals from US FDA (49 Final approvals and 2 tentative approvals).

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India has enclosed the press release today titled ‘Granules India Limited Received ANDA Approval for Guaifenesin and Pseudoephedrine Hydrochloride Extended-Release Tablets’.

The above information is a part of company’s filings submitted to BSE.

Granules now have a total of 52 ANDA approvals from US FDA

Granules India is currently trading at Rs. 306.85, up by 4.90 points or 1.62% from its previous closing of Rs. 301.95 on the BSE.

The scrip opened at Rs. 301.80 and has touched a high and low of Rs. 307.65 and Rs. 301.80 respectively. So far 21178 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 362.25 on 14-Jan-2022 and a 52 week low of Rs. 227.00 on 20-Jun-2022.

Last one week high and low of the scrip stood at Rs. 314.90 and Rs. 300.05 respectively. The current market cap of the company is Rs. 7549.34 crore.

The promoters holding in the company stood at 41.98%, while Institutions and Non-Institutions held 26.16% and 31.85% respectively.

Granules India has received Abbreviated New Drug Application (ANDA) approval for Loperamide Hydrochloride and Simethicone Tablets, 2 mg/125 mg (OTC) from US Food & Drug Administration (USFDA). It is bioequivalent to the reference listed drug product, Imodium Multi-Symptom Relief Tablets, 2 mg/125 mg, of Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division.

Loperamide Hydrochloride and Simethicone Tablets are indicated to relieve symptoms of diarrhea plus bloating, pressure and cramps, commonly referred to as gas. Granules now have a total of 52 ANDA approvals from US FDA (50 Final approvals and 2 tentative approvals).

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India has informed that it enclosed the press release today titled ‘Granules India Limited Received ANDA Approval for Loperamide Hydrochloride and Simethicone Tablets’.

The above information is a part of company’s filings submitted to BSE.

Pursuant to provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Granules India has informed that it enclosed the details of the meeting wherein the officials of the Company will be meeting a group of Analysts/Investors/Fund at Hotel Grand Hyatt, Mumbai.

The above information is a part of company’s filings submitted to BSE.

The facility spread across 100 acres, will be commissioned in a phase wise manner

Granules India is currently trading at Rs. 329.30, up by 8.95 points or 2.79% from its previous closing of Rs. 320.35 on the BSE.

The scrip opened at Rs. 322.70 and has touched a high and low of Rs. 329.35 and Rs. 322.00 respectively. So far 9504 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 381.25 on 04-Nov-2022 and a 52 week low of Rs. 227.00 on 20-Jun-2022.

Last one week high and low of the scrip stood at Rs. 331.80 and Rs. 314.00 respectively. The current market cap of the company is Rs. 7753.84 crore.

The promoters holding in the company stood at 41.93%, while Institutions and Non-Institutions held 26.67% and 31.40% respectively.

Granules India has entered into a strategic partnership with Greenko ZeroC to collaborate for Green Molecule Solutions and its wider applications in pharmaceuticals to build a leadership position in sustainability and circular economy initiatives and be a pioneer in the industry.

Granules & Greenko ZeroC will develop and promote State-of-the-art Integrated Green Pharmaceutical Zones (GPZ) with first collaboration in Kakinada, Andhra Pradesh. Granules will build a green field facility based on sustainability principles for large scale manufacturing of key starting materials (KSMs), Intermediates, APIs and fermentation-based products. The facility spread across 100 acres, will be commissioned in a phase wise manner. The estimated cost of the project will be approximately Rs 2,000 crore over five years.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India has informed that it enclosed the press release today titled ‘Granules Enters into a Strategic Partnership With Greenko ZeroC To Enable Carbon Free Energy and Green Molecule Solutions’.

The above information is a part of company’s filings submitted to BSE.

Granules India has informed that it enclosed the press release today titled ‘Granules Pharmaceuticals Inc., Receives ANDA Approval for Amphetamine Mixed Salts ER Capsules’.

The above information is a part of company’s filings submitted to BSE.

This product will be manufactured at Granules manufacturing facility in Chantilly, Virginia and is expected to be launched shortly

Granules India is currently trading at Rs. 313.30, up by 1.20 points or 0.38% from its previous closing of Rs. 312.10 on the BSE.

The scrip opened at Rs. 312.60 and has touched a high and low of Rs. 314.70 and Rs. 311.00 respectively. So far 5821 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 381.25 on 04-Nov-2022 and a 52 week low of Rs. 227.00 on 20-Jun-2022.

Last one week high and low of the scrip stood at Rs. 316.35 and Rs. 307.70 respectively. The current market cap of the company is Rs. 7554.15 crore.

The promoters holding in the company stood at 42.02%, while Institutions and Non-Institutions held 28.41% and 29.56% respectively.

The US Food & Drug Administration (US FDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, Inc (GPI)., a wholly-owned foreign subsidiary of Granules India, for Amphetamine Mixed Salts, 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg Extended-Release (ER) capsules. It is bioequivalent to the reference listed drug product (RLD), Adderall XR Extended-Release capsules of Takeda Pharmaceuticals USA Inc. This product will be manufactured at Granules manufacturing facility in Chantilly, Virginia and is expected to be launched shortly.

Mixed Salts of a Single-Entity Amphetamine ER Capsules are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Granules now have a total of 53 ANDA approvals from US FDA (51 Final approvals and 2 tentative approvals). The current annual U.S. market for Amphetamine Mixed Salts ER capsule product is approximately $1.56 Billion, according to MAT Nov 2022, IQVIA/IMS Health.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Pursuant to regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Granules India has informed that the transcript of the earnings conference call of the Company held on January 24, 2023 for the third quarter and nine-months ended on December 31, 2022 has been enclosed and uploaded on the website of the Company at the below-mentioned link: https://granulesindia.com/investors/investor-resources/earnings-call-transcripts/.

The above information is a part of company’s filings submitted to BSE.

Granules India has informed that it enclosed the press release today titled ‘Granules India Limited Received ANDA Approval for Losartan Potassium Tablets’.

The above information is a part of company’s filings submitted to BSE.

Quarterly Results

Quarterly Results

Buy Back of Shares & Quarterly Results

Rs.0.7500 per share(75%)Final Dividend

Final Dividend & Audited Results

Re.0.25000 per share (25%) Third Interim Dividend

Interim Dividend & Quarterly Results

Re.0.2500 per share (25%) Second Interim Dividend

Quarterly Results & Interim Dividend

First Interim Dividend of Rs.0.25/- (25%)

Rs.0.7500 per share(75%)Final Dividend

Quarterly Results & Interim Dividend

The company now have a total of 51 ANDA approvals from US FDA

Granules India has received approval from US Food & Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Guaifenesin and Pseudoephedrine Hydrochloride Extended-Release (ER) Tablets, 600 mg/60 mg and 1200 mg/120 mg (OTC). It is bioequivalent to the reference listed drug product, Mucinex D Extended-Release Tablets, 600 mg/60 mg and 1200 mg/120 mg, of RB Health (US) LLC.

Guaifenesin and Pseudoephedrine Hydrochloride ER Tablets are used to loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive; temporarily relieve nasal congestion due to common cold, hay fever, upper respiratory allergies; temporarily restores freer breathing through the nose; promotes nasal and/or sinus drainage; and temporarily relieves sinus congestion and pressure. Granules now have a total of 51 ANDA approvals from US FDA (49 Final approvals and 2 tentative approvals).

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules now have a total of 52 ANDA approvals from US FDA

Granules India has received Abbreviated New Drug Application (ANDA) approval for Loperamide Hydrochloride and Simethicone Tablets, 2 mg/125 mg (OTC) from US Food & Drug Administration (USFDA). It is bioequivalent to the reference listed drug product, Imodium Multi-Symptom Relief Tablets, 2 mg/125 mg, of Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division.

Loperamide Hydrochloride and Simethicone Tablets are indicated to relieve symptoms of diarrhea plus bloating, pressure and cramps, commonly referred to as gas. Granules now have a total of 52 ANDA approvals from US FDA (50 Final approvals and 2 tentative approvals).

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

The facility spread across 100 acres, will be commissioned in a phase wise manner

Granules India has entered into a strategic partnership with Greenko ZeroC to collaborate for Green Molecule Solutions and its wider applications in pharmaceuticals to build a leadership position in sustainability and circular economy initiatives and be a pioneer in the industry.

Granules & Greenko ZeroC will develop and promote State-of-the-art Integrated Green Pharmaceutical Zones (GPZ) with first collaboration in Kakinada, Andhra Pradesh. Granules will build a green field facility based on sustainability principles for large scale manufacturing of key starting materials (KSMs), Intermediates, APIs and fermentation-based products. The facility spread across 100 acres, will be commissioned in a phase wise manner. The estimated cost of the project will be approximately Rs 2,000 crore over five years.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Gagillapur facility manufactures Finished Dosages (FDs) and Pharmaceutical Formulation Intermediates

United States Food and Drug Administration (USFDA) has completed Pre-Approval inspection (PAI) at Granules India’s Gagillapur facility located at Hyderabad, Telangana, from January 09, 2023 to January 13, 2023 with 3 observations and the Company will respond to these observations within the stipulated time period.

Gagillapur facility manufactures Finished Dosages (FDs) and Pharmaceutical Formulation Intermediates (PFIs).

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

This product will be manufactured at Granules manufacturing facility in Chantilly, Virginia and is expected to be launched shortly

The US Food & Drug Administration (US FDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, Inc (GPI)., a wholly-owned foreign subsidiary of Granules India, for Amphetamine Mixed Salts, 5mg, 10mg, 15mg, 20mg, 25mg, and 30mg Extended-Release (ER) capsules. It is bioequivalent to the reference listed drug product (RLD), Adderall XR Extended-Release capsules of Takeda Pharmaceuticals USA Inc. This product will be manufactured at Granules manufacturing facility in Chantilly, Virginia and is expected to be launched shortly.

Mixed Salts of a Single-Entity Amphetamine ER Capsules are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Granules now have a total of 53 ANDA approvals from US FDA (51 Final approvals and 2 tentative approvals). The current annual U.S. market for Amphetamine Mixed Salts ER capsule product is approximately $1.56 Billion, according to MAT Nov 2022, IQVIA/IMS Health.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules now has a total of 54 ANDA approvals from USFDA

Granules India has received US Food & Drug Administration (USFDA) approval for its Abbreviated New Drug Application (ANDA) for Losartan Potassium Tablets USP, 25 mg, 50 mg, and 100 mg. It is bioequivalent to the reference listed drug product (RLD), Cozaar Tablets of Organon LLC. Granules now has a total of 54 ANDA approvals from US FDA (52 Final approvals and 2 tentative approvals).

Losartan potassium tablets are indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. The current annual U.S. market for Losartan potassium Tablets is approximately $336 Million, according to MAT Dec 2022, IQVIA/IMS Health.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).